Pharmaceutical News

RSS

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

Bringing clarity to a decades-long debate, a national team of researchers led by experts from the Perelman School of Medicine at the University of Pennsylvania has found that adding clot-busting medications known as thrombolytics to conventional approaches when treating sudden-onset pulmonary embolism patients is associated with 47 percent fewer deaths than using standard intravenous or under-the-skin anticoagulant medications alone.

18 Jun 2014

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA's guidance.

18 Jun 2014

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.

18 Jun 2014

Hypertension medication may cause metabolic-related adverse events in older adults

Adults over 65 who have recently begun thiazide diuretics are at a greater risk for developing metabolic-related adverse events, researchers at UT-Southwestern Medical Center have found.

18 Jun 2014

Researchers find sharp increase in deaths from commonly prescribed painkillers in US, Canada

The number of deaths involving commonly prescribed painkillers is higher than the number of deaths by overdose from heroin and cocaine combined, according to researchers at McGill University.

18 Jun 2014

Single dose restores normal cellular signaling in mouse model of autism

In a further test of a novel theory that suggests autism is the consequence of abnormal cell communication, researchers at the University of California, San Diego School of Medicine report that an almost century-old drug approved for treating sleeping sickness also restores normal cellular signaling in a mouse model of autism, reversing symptoms of the neurological disorder in animals that were the human biological age equivalent of 30 years old.

18 Jun 2014

BIPI, Lilly announce resubmission of empagliflozin NDA to FDA for treatment of type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the U.S. Food and Drug Administration (FDA).

17 Jun 2014

Provepharm, DFKC partner to launch Methylthioninium chloride Proveblue in Germany

Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie, a German leader in the manufacture and supply of organ preservation solutions and antidote pharmaceuticals, today announce that they have entered into a partnership to launch Provepharm’s drug product Methylthioninium chloride Proveblue 5mg/ml solution for injection (the Product) in Germany, for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.

17 Jun 2014

Researchers demonstrate potential of retinoic acid in preventing type 2 diabetes complications

At a time when obesity, type 2 diabetes, and their complications are a veritable epidemic worldwide, researchers at the University of Montreal and CHUM Research Centre (CRCHUM) recently demonstrated the potential of retinoic acid (RA), a derivative of Vitamin A, in treating obesity and type 2 diabetes and preventing their cardiovascular complications.

17 Jun 2014

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.

16 Jun 2014

Researchers develop rapid-acting antidepressants for treatment-resistant depression

UT Southwestern Medical Center researchers have generated fresh insights that could aid in the development of rapid-acting antidepressants for treatment-resistant depression.

13 Jun 2014

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

New data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) show that the newly-approved infliximab biosimilar CT-P13 achieves statistically similar improvements in disease activity, disability and mobility in patients with Ankylosing Spondylitis (AS) compared to its original reference product infliximab (INX).

13 Jun 2014

2 medications equally effective in treating major epileptic brain seizures in children

A recently published clinical study in the Journal of the American Medical Association has answered an urgent question that long puzzled ER pediatricians: Is the drug lorazepam really safer and more effective than diazepam - the U.S. Food and Drug Administration-approved medication as first line therapy most often used by emergency room doctors to control major epileptic seizures in children?

13 Jun 2014

Steroid injections can provide pain relief for mom without affecting baby

From weird cravings to swollen feet, pregnant women deal with a lot during those nine months Some women even suffer from hand pain when there are simple, baby-safe options to treat the symptoms.

13 Jun 2014

Study uncovers why statins increase diabetes risk

McMaster University researchers may have found a novel way to suppress the devastating side effect of statins, one of the worlds' most widely used drugs to lower cholesterol and prevent heart disease.

13 Jun 2014

Use of opioid linked to higher levels of dissatisfaction following spine surgery

A new study appearing in the Journal of Bone and Joint Surgery (JBJS) links the use of opioid pain relievers (prescription medications, such as Percocet) to less improvement and higher levels of dissatisfaction following spine surgery.

13 Jun 2014

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Duloxetine Delayed-release Capsules.

12 Jun 2014

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

12 Jun 2014

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).

12 Jun 2014

Pharmaceutical News

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Clot-busting medications for treating pulmonary embolism patients linked with fewer deaths

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Study compares effectiveness of selumetinib, chemotherapy in patients with advanced uveal melanoma

Hypertension medication may cause metabolic-related adverse events in older adults

Researchers find sharp increase in deaths from commonly prescribed painkillers in US, Canada

Single dose restores normal cellular signaling in mouse model of autism

BIPI, Lilly announce resubmission of empagliflozin NDA to FDA for treatment of type 2 diabetes

Provepharm, DFKC partner to launch Methylthioninium chloride Proveblue in Germany

Researchers demonstrate potential of retinoic acid in preventing type 2 diabetes complications

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

Researchers develop rapid-acting antidepressants for treatment-resistant depression

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

2 medications equally effective in treating major epileptic brain seizures in children

Steroid injections can provide pain relief for mom without affecting baby

Study uncovers why statins increase diabetes risk

Use of opioid linked to higher levels of dissatisfaction following spine surgery

Breckenridge announces launch of Duloxetine Delayed-release Capsules

Cancer drug offers protection against thrombosis

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News